Nexsen advances StrepSure® toward U.S. market entry following FDA Pre Submission feedback that clarifies and de risks its regulatory pathway.
Nexsen (ASX:NXN) has secured $500,000 in non-dilutive Federal funding to extend its rapid Group B Streptococcus diagnostic technology from maternal
Nexsen has commenced formal engagement with the US Food and Drug Administration for its GBS Rapid Sensor, marking a defined
Nexsen Limited (ASX:NXN) strengthens its global clinical adoption potential with the strategic appointment of internationally recognised surgeon-scientist Professor Shekhar Kumta
Nexsen Limited (ASX:NXN) has begun clinical trials for its StrepSure® GBS Rapid Sensor, marking a pivotal step toward transforming real-time
